Navigation Links
Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
Date:3/21/2013

eries is very exciting and gratifying milestone for us."

Concurrent with FREEDOM-1, Intarcia will also be conducting an open-label study, called FREEDOM-1 HBL (high baseline), in patients who meet all eligibility criteria for FREEDOM-1, but whose baseline HbA1c is greater than 10%. All patients in this study will be treated with ITCA 650 20 mcg/d for the first 3 months and with ITCA 650 60 mcg/d for the next 6 months.

About the FREEDOM Program

The FREEDOM program is designed to evaluate the safety and efficacy of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes. Intarcia expects to enroll greater than 4,000 patients at more than 500 clinical trial sites in more than 30 countries. The clinical studies will cover a broad range of patients whose diabetes is not controlled by oral anti-diabetes medications including metformin and metformin-based combinations. FREEDOM-1 is a U.S.-only, placebo-controlled, double-blind study comparing ITCA 650 doses of 40 mcg/d and 60 mcg/d to placebo; the FREEDOM-2 study will be a 500-patient, global, active-comparator controlled, double-blind, double-dummy study in patients on metformin only, comparing ITCA 650 20 mcg/d for 13 weeks plus ITCA 650 60 mcg/d for 39 weeks to patients taking sitagliptin (Januvia®, Merck); FREEDOM-CVO is a global, placebo-controlled cardiovascular outcomes study that will examine the safety of ITCA 650 at 60 mcg/d vs. placebo in approximately 3,000 patients on a variety of approved anti-diabetes therapies.

About ITCA 650

ITCA 650 (continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
3. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
4. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
5. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
6. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
7. PQA and CECity Launch Joint Venture to Deliver First National Pharmacy Quality Measurement, Benchmarking and Reporting Platform for Pharmacies and Health Plans
8. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
9. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
10. Wyckoff Heights Medical Center Is First New York Hospital to Offer Asthmapolis Mobile Asthma Management Program
11. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation ... device-based mechanical circulatory support therapies to save, support and ... in the 2014 Morgan Stanley Global Healthcare Conference on ... , President and Chief Executive Officer, will provide an ... Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... -- According to a new market ... (SFE, Cold Pressed, Organic Solvent, & Others), and by ... & Others) - Global Trends & Forecast to ... Amaranth Seed Oil Market with an analysis and ... value. The Amaranth Seed Oil Market size in ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), a ... markets, today announced first quarter 2011 financial results. ... 31, 2011, net revenue was $10.7 million, up from $10.1 ... despite a brief, planned halt in shipments of Acetadote during ...
... NEW YORK, May 4, 2011 Robotic prostatectomy and ... Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive ... appeared on FOX-NY,s Good Day New York to discuss the successes ... benefits it has over other treatment options, making robotic surgery ...
Cached Medicine Technology:Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports First Quarter 2011 Financial Results 10Dr. David B. Samadi Discusses Why Robotic Surgery is Quickly Becoming the Go-To Standard for Prostate Cancer Treatment 2Dr. David B. Samadi Discusses Why Robotic Surgery is Quickly Becoming the Go-To Standard for Prostate Cancer Treatment 3
(Date:8/29/2014)... new report released yesterday by the Mental Health ... mental health training and education that police personnel ... prominent issue for Canada,s police community, and today,s ... law enforcement and people with mental illnesses," says ... with an interest in the area of police ...
(Date:8/29/2014)... Today, Gen. Arthur T. Dean, Chairman ... (CADCA) , the nation’s leading substance abuse prevention organization, ... intent to nominate Michael Botticelli as the Director of ... Obama’s decision to nominate Michael Botticelli as our nation’s ... hold this important position at this time in our ...
(Date:8/29/2014)... 2014 Thirteen Novant Health ... Great 100 Nurses in North Carolina list by ... and provides scholarships to nursing students at all levels ... Novant Health Presbyterian Medical Center are: Rea Buie, ... King, Lissa Ready, Amber Segerlin, Carmen Smith, Melissa Stafford ...
(Date:8/29/2014)... 29, 2014 Edvance360, a leading provider ... for online teaching, as well as 2011 winner and ... Learning Management System, announced that Brooke Education Services, Northwest ... Group, Interactive Advertising Bureau of Canada (IAB Canada), StarSVCS, ... “We are delighted to welcome each new client to ...
(Date:8/29/2014)... 2014 (HealthDay News) -- Selling cigarettes in plain packages ... and doesn,t harm sales in small stores, according to ... by the tobacco industry when it tried to prevent ... to introduce plain packaging for tobacco products in 2012. ... and the U.K. Researchers surveyed nearly 2,000 adult ...
Breaking Medicine News(10 mins):Health News:Report advocates improved police training 2Health News:CADCA Statement on Nomination of Michael Botticelli as U.S. Drug Czar 2Health News:Great 100 Honors 13 Novant Health Nurses 2Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Study Counters Critics of Plainer Cigarette Packaging 2
... , ... expert in mobile user management, today extended its comprehensive software suite to manage, track ... announcement follows last month,s highly successful launch of BoxTone v5.0, which included new support ... Mobile. , ...
... ... edge vibration exercise technology into South America, beginning in Argentina, Chile and Uruguay. All ... are now available in South America. , ... (Vocus) November 10, 2009 -- WAVE (Whole-Body Advanced Vibration Exercise), ...
... ... has unveiled a new website. Residents of Washington who need legal advice can now ... ... Firm Carrington Nuamah, P.C. has launched a new website at www.carringtonnuamah.com . Lawyers ...
... ... fast-track preparedness and response efforts for the H1N1 pandemic have a new resource at ... ... preparedness and response efforts for the H1N1 pandemic have a new resource at their ...
... Time for Senate to Act , WASHINGTON, Nov. 9 ... Win: , After generations of struggle and decades of delay, the ... to pass historic reform legislation to assure every American, regardless of ... House,s action this November is why working men and women turned ...
... health care reform - the Affordable Health Care for America ... November 7, 2009 - mandates several significant changes to the tax ... to appear in any Senate version, requiring extensive reconciliation to reach ... on the tax provisions of the legislation, detailing differences ...
Cached Medicine News:Health News:BoxTone Delivers Enterprise Mobile User Management for Google Android 2.0 Smartphones 2Health News:BoxTone Delivers Enterprise Mobile User Management for Google Android 2.0 Smartphones 3Health News:WAVE's Revolutionary Whole-Body Advanced Vibration Exercise Is Now Available in South America 2Health News:Seattle Law Firm Carrington Nuamah Launches New Website for Personal Injury, Bankruptcy, Immigration and Estate Law 2Health News:New H1N1 Flu Guide Offers Practical Tools and Tips for HR Professionals 2Health News:New H1N1 Flu Guide Offers Practical Tools and Tips for HR Professionals 3Health News:Statement of Anna Burger, Chair, Change to Win, on U.S. House Vote for Health Care Reform 2Health News:CCH Briefing Details Tax Provisions of House Health Care Bill 2
Inquire...
... The GENIE is the proven electrophoretic transfer apparatus ... field uniformity. Its design allows for a very ... with a low voltage power source such as ... volts/cm. The result is exceptionally rapid and exact ...
... cassettes, 4 fiber pads, modular electrode assembly, ... with cables, and instructions. The Mini ... mini electrophoresis system (see Mini-Vertical Electrophoresis Systems), ... Its modular electrode assembly transfers two 7.5 ...
... 2 gel holder cassettes, cell ... fiber pads, blot absorbent paper ... Trans-Blot transfer cell, used with ... performs efficient, high-intensity electrophoretic transfers. ...
Medicine Products: